American Journal of Cardiology
Volume 102, Issue 9 , Pages 1119-1124 , 1 November 2008

Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction

  • Herbert D. Aronow, MD, MPH

      Affiliations

    • Clinical Scholars Program, Michigan Heart and Vascular Institute at St. Joseph Mercy Hospital, Ann Arbor, Michigan
    • Corresponding Author InformationCorresponding author: Tel: 734-712-8000; Fax: 734-712-8010
    • ,
  • A. Michael Lincoff, MD

      Affiliations

    • Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Martin J. Quinn, MD, PhD

      Affiliations

    • St. Vincents University Hospital, Dublin, Ireland
    • ,
  • A. Thomas McRae, MD

      Affiliations

    • Centennial Heart Cardiovascular Consultants, Nashville, Tennessee
    • ,
  • Hitinder S. Gurm, MD

      Affiliations

    • Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, Michigan
    • ,
  • Penny L. Houghtaling, MS

      Affiliations

    • Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • Robert A. Harrington, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, North Carolina
    • ,
  • Franz Van de Werf, MD, PhD

      Affiliations

    • Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Eric J. Topol, MD

      Affiliations

    • Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California
    • ,
  • Michael S. Lauer, MD

      Affiliations

    • Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
    • ,
  • GUSTO IIb and PURSUIT Trial Investigators

Received 27 February 2008 ,Revised 17 June 2008 ,Accepted 17 June 2008.

References 

  1. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes (The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators). N Engl J Med. 1996;335:775–782
  2. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy). N Engl J Med. 1998;339:436–443
  3. Hackel DB, Reimer KA, Ideker RE, Mikat EM, Hartwell TD, Parker CB, et al Comparison of enzymatic and anatomic estimates of myocardial infarct size in man. Circulation. 1984;70:824–835
  4. Licka M, Zimmermann R, Zehelein J, Dengler TJ, Katus HA, Kubler W. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart. 2002;87:520–524
  5. Roberts R, Ambos HD, Sobel BE. Estimation of infarct size with MB rather than total CK. Int J Cardiol. 1983;2:479–492
  6. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–763
  7. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333
  8. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25:2084–2106
  9. Jones SP, Gibson MF, Rimmer DM, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 2002;40:1172–1178
  10. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol. 2004;44:348–355
  11. Bybee KA, Kopecky SL, Williams BA, Murphy JG, Scott Wright R. Reduced creatine kinase release with statin use at the time of myocardial infarction. Int J Cardiol. 2004;96:461–466
  12. Hoffmann R, Haager P, Suliman H, Christott P, Radke P, Blindt R, et al. Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion. Am J Cardiol. 2008;101:139–143
  13. Spencer FA, Fonarow GC, Frederick PD, Wright RS, Every N, Goldberg RJ, et al. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Intern Med. 2004;164:2162–2168
  14. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718
  15. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  16. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063–1068
  17. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102:3104–3110
  18. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res. 2002;105:285–290
  19. Hoshida S, Nishida M, Yamashita N, Igarashi J, Hori M, Kamada T, et al. Amelioration of severity of myocardial injury by a nitric oxide donor in rabbits fed a cholesterol-rich diet. J Am Coll Cardiol. 1996;27:902–909
  20. Hoshida S, Yamashita N, Otsu K, Kuzuya T, Hori M. Cholesterol feeding exacerbates myocardial injury in Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol. 2000;278:H256–H262
  21. Bulhak AA, Gourine AV, Gonon AT, Sjoquist PO, Valen G, Pernow J. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Acta Physiol Scand. 2005;183:151–159
  22. Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69:904–910
  23. Spencer FA, Goldberg RJ, Gore JM, Fox KA, Avezum A, Agnelli G, et al. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein > or = 100 mg/dl versus <100 mg/dl. Am J Cardiol. 2007;100:913–918
  24. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25:445–451
  25. Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 1996;164:208–211
  26. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316
  27. Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med. 2000;108:496–499
  28. EUROASPIRE Study Group. EUROASPIRE (A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events). Eur Heart J. 1997;18:1569–1582
  29. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group). N Engl J Med. 1999;341:410–418

 Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) was supported by COR Therapeutics, Inc., San Francisco, California, and Schering-Plough Research Institute, Kenilworth, New Jersey; and Global Use of Streptokinase or t-PA for Occluded Coronary Arteries IIb (GUSTO IIb) was supported by Ciba-Geigy, Inc., Summit, New Jersey; Boehringer-Mannheim, Indianapolis, Indiana; and Guidant Corp., Redwood City, California.

PII: S0002-9149(08)01134-X

doi: 10.1016/j.amjcard.2008.06.032

American Journal of Cardiology
Volume 102, Issue 9 , Pages 1119-1124 , 1 November 2008

Article Tools

* Image Usage & Resolution